Company Overview and News

 
Skeena Initiates Phase II Underground Drilling at Snip

2018-04-03 globenewswire
VANCOUVER, B.C., April 03, 2018 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX.V:SKE) (OTCQX:SKREF) (“Skeena” or the “Company”) is pleased to announce the commencement of underground drilling at its 100% owned Snip Project located in the Golden Triangle of British Columbia. The budgeted Phase II drill program totalling 11,000 metres is being performed from the existing underground infrastructure utilizing two drill rigs.
Upvote Downvote

 
Skeena Closes Oversubscribed Private Placement

2018-03-29 globenewswire
VANCOUVER, British Columbia, March 29, 2018 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX.V:SKE) (“Skeena” or the “Company”) is pleased to announce that it has closed its previously announced private placement of units (the “Units”) and flow-through common shares (the “FT Shares”) of the Company (the “Offering”) pursuant to an agency agreement dated March 29, 2018 (the “Agency Agreement”) between the Company and PI Financial Corp.
Upvote Downvote

 
Skeena Financing Oversubscribed and Upsized

2018-03-19 globenewswire
VANCOUVER, British Columbia, March 19, 2018 (GLOBE NEWSWIRE) -- Skeena Resources Limited (TSX.V:SKE) (OTCQX:SKREF) (“Skeena” or the “Company”) is pleased to announce that the best efforts private placement financing previously announced on March 13, 2018 (the “Offering”) is now oversubscribed and as a result the Company has upsized the Offering. The Offering will now consist of the sale of approximately 9,139,451 units (the “Units”) and approximately 4,223,572 flow-through common shares (the “FT Shares”) of the Company to raise aggregate gross proceeds of approximately C$8.
Upvote Downvote

 
BRIEF-Skeena Announces $6.0 Million Private Placement Financing

2018-03-13 reuters
* SKEENA RESOURCES - PRIVATE PLACEMENT OF UP TO 5 MILLION UNITS AND UP TO 4.3 MILLION FLOW-THROUGH SHARES OF CO
Upvote Downvote

 
News Release Canarc Signs Agreement with Barrick Gold and Skeena Resources on Its 33.33% Carried Interest in Claims at the Eskay Creek Gold Mine

2017-12-21 accesswire
VANCOUVER / ACCESSWIRE / December 21, 2017 / Canarc Resource Corp. (TSX: CCM; OTCQB: CRCUF; FRA: CAN) has entered into an agreement with Barrick Gold Inc ("Barrick") and Skeena Resources Ltd. ("Skeena") involving its 33.3% carried interest in certain mining claims adjacent to the past-producing Eskay Creek Gold mine located in northwest British Columbia.
Upvote Downvote

 
BRIEF-Skeena Resources Secures Option To Acquire Eskay Creek

2017-12-18 reuters
* SKEENA RESOURCES - SIGNS AGREEMENT WITH BARRICK GOLD GRANTING AN OPTION FOR CO TO ACQUIRE A 100% INTEREST IN PAST-PRODUCING ESKAY CREEK PROPERTY
Upvote Downvote

 
Sandstorm Gold's (SAND) CEO Nolan Watson on Q3 2017 Results - Earnings Call Transcript

2017-11-05 seekingalpha
Good morning. My name is Leonie, and I will be your conference operator today. At this time, I would like to welcome everyone to the Sandstorm Gold Conference Call. All lines have been placed on mute to prevent any background noise. Please be aware that some of the commentary may contain forward-looking statements. There can be no assurance that forward-looking statements will be proved to be accurate as actual results and future events could differ materially from those anticipated in such statements.
Upvote Downvote

3
My Watchlist Of The Gold Mining Players In The Red Hot BC Golden Triangle Part 2

2017-10-13 seekingalpha
The Golden Triangle in British Columbia hosts some of the highest grade ore bodies in the world. Recently, it has seen a renewed interest by the metals explorers community.
Upvote Downvote

 
Resource Sector Digest: Revisiting The Rainy River Chook Raffle

2017-10-12 seekingalpha
Alleged inability to organize a chook raffle will be re-visited in this week's Resource Sector Digest.
Upvote Downvote

2
Gold Bull Portfolio: Month In Review

2017-10-04 seekingalpha
Here's a look at the performance of the gold bull portfolio and a recap of September's top news in the gold mining sector.
Upvote Downvote

 
BRIEF-Skeena announces $6 million strategic investment

2017-10-02 reuters
* Skeena Resources Ltd - net proceeds of financing will be used to fund on-going exploration programs
Upvote Downvote

 
Supreme Court of British Columbia Rules in Favour of Skeena

2017-08-03 marketwired
VANCOUVER, BC--(Marketwired - August 03, 2017) - Skeena Resources Limited (TSX VENTURE: SKE) ("Skeena" or the "Company") is pleased to announce that the Supreme Court of British Columbia has ruled in favour of its subsidiary, Sona Resources ("Sona") regarding a dispute about the Company's option to earn a 100% equity interest in the mineral and Crown-granted claims referred to as the Elizabeth property.
Upvote Downvote

 
Skeena Exercises Option to Acquire Snip

2017-07-31 marketwired
VANCOUVER, BC--(Marketwired - July 31, 2017) - Skeena Resources Limited (TSX VENTURE: SKE) ("Skeena" or the "Company") is pleased to announce that it has exercised its option (the "Option") to acquire a 100% interest in the past-producing, high-grade Snip gold property ("Snip" or the "Property") located in the Golden Triangle of British Columbia from Barrick Gold Corp. ("Barrick"). The Option was granted pursuant to an option agreement (the "Option Agreement") between Skeena and Barrick dated March 22, 2016.
Upvote Downvote

 
Concept Capital Management Files Early Warning Report

2017-06-15 marketwired
VANCOUVER, BC--(Marketwired - June 15, 2017) - Concept Capital Management Ltd. ("Concept") announces that it acquired for a purchase price of C$999,960, direct ownership of 19,999,200 units (the "Units") of Skeena Resources Limited ("Skeena") (TSX VENTURE: SKE), of 650 - 1021 West Hastings St., Vancouver, BC V6E 0C3, at a price of C$0.05 per Unit pursuant to a private placement of Units on June 13, 2017 (the "Private Placement").
Upvote Downvote

Related Articles

GNCA: Genocea Biosciences Analysis and Research Report

11h - Asif

Overview Genocea Biosciences is a biopharmaceutical company that discovers and develops novel cancer vaccines. The company use its proprietary discovery platform, ATLAS, to recall a patient’s pre-existing CD4+ and CD8+ T cell immune responses to their tumor to identify antigens for inclusion in vaccines that are designed to act through T cell (or cellular) immune responses. The company believe that using ATLAS to identify antigens for inclusion in cancer vaccines could lead to more immunogenic and efficacious cancer vaccines. In September 2017, the company announced a strategic shift to immuno-oncology and a focus on the development of neoantigen cancer vaccines. Currently, all of its research programs and product candidates in active development are at the preclinical stage. The company's most advanced program is its preclinical immuno-oncology program, GEN-009, a neoantigen cancer vaccine. The GEN-009 program uses ATLAS to identify patient neoantigens, or newly formed anti...

AMZN: Amazon.com, Inc Analysis and Research Report

12h - Asif

Overview Amazon.com opened its virtual doors on the World Wide Web in July 1995. The company seek to be Earth’s most customer-centric company. Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. In each of its segments, the company serve its primary customer sets, consisting of consumers, sellers, developers, enterprises, and content creators. In addition, the company provide services, such as advertising services and co-branded credit card agreements. Amazon has organized its operations into three segments: North America, International, and Amazon Web Services (“AWS”). These segments reflect the way the Company evaluates its business performance and manages its operations. Additional information on its operating segments and its net sales is contained in Item 8 of Part II, “Financial Statements and Supplementary Data—Note 11—Segment Information.” The compan...

LPCN: Lipocine Inc Analysis and Research Report

2018-04-23 - Asif

Overview Lipocine is a specialty pharmaceutical company focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men’s and women’s health. The company's proprietary delivery technologies are designed to improve patient compliance and safety through orally available treatment options. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Lipocine has a portfolio of proprietary product candidates designed to produce favorable pharmacokinetic (“PK”) characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. The company's lead product candidate, TLANDO™, is an oral testosterone replacement therapy (“TRT”) and is currently under review by the United States Food and Drug Administration (“FDA”) with a Prescription Drug User Fee Act (“...